The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Real-world efficacy & safety of elranatamab in R/R myeloma: an IMWG immunotherapy database analysis
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses the real-world efficacy and safety of elranatamab, a BCMA-targeting bispecific antibody, in patients with relapsed/refractory (R/R) multiple myeloma, presenting data from an analysis of the International Myeloma Working Group (IMWG) immunotherapy database. The real-world data demonstrate response and progression-free survival (PFS) rates similar to those in the MagnetisMM-3 trial (NCT04649359), with the toxicity profile being as expected. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
